In Kampala, the clinical conversation about hypertension has quietly shifted. Uganda's national guidelines, updated within the last few years, now recommend a blood pressure target below 130/80 mmHg for most adults with hypertension. That aligns with international evidence from trials like SPRINT and STEP. But walk into a typical private clinic in the city, and you will likely find clinicians still titrating medications to the older, more familiar goal of 140/90. The gap is not driven by a lack of evidence; it is driven by habit, workload, and a measurement problem that makes even the tightest guideline feel like guesswork.

Guidelines Say 130/80, Clinics Still Chase 140/90

The updated Ugandan guidelines reflect a global shift. For years, the standard answer for most adults with hypertension was to bring systolic pressure below 140 mmHg. That threshold was simple, memorable, and embedded in decades of clinical habit. The new recommendation, below 130/80, emerged from trials showing that more intensive control reduces cardiovascular events, though the absolute benefits are modest for many patients.

Yet in Kampala's busy outpatient departments, the old target persists. A physician seeing 50 to 80 patients a day, with consultations often under five minutes, rarely has time to recalculate risk or debate the nuances of a 10-point difference. The 140/90 number is what they were taught in medical school, what their senior colleagues used, and what the drug charts in front of them assume.

Fear of overtreatment plays a role. Clinicians worry that pushing systolic pressure below 130 might cause dizziness, falls, or acute kidney injury in patients who are often older, malnourished, or living with chronic infections. The guidelines acknowledge this risk but do little to help a frontline doctor weigh it in real time.

The result is a quiet divergence: policy says one thing, practice does another. Patients leave with prescriptions adjusted to a number that is now officially outdated, and the gap between evidence and action widens with every clinic day.

The Wrist Cuff Paradox: Precise Numbers, Airy Calibration

Compounding the target gap is the device problem. Wrist blood pressure monitors have become popular in Kampala's private clinics. They are compact, easy to use, and cheaper than quality upper-arm devices. But they measure pressure at the radial artery, not the brachial artery, and the readings can vary widely depending on wrist position relative to the heart.

Guidelines from major cardiology societies assume upper-arm cuffs with validated devices. That assumption collapses when a clinic's only monitor is a wrist cuff purchased from a market stall, with no documentation of clinical validation. The numbers it produces look precise, down to the last millimeter of mercury, but they may be measuring what clinicians wryly call diastolic air.

Device validation is rarely checked in Kampala. A 2020 survey of blood pressure devices in Ugandan health facilities found that many had never been calibrated, and some had been dropped or were decades old. Wrist cuffs add another layer of variability: even a small change in wrist height can shift readings by 10 mmHg or more.

When clinicians treat to a number that is not reliably measuring true blood pressure, they are making decisions on a foundation of air. A patient might be pushed onto a third antihypertensive because a wrist cuff read 145/90, when an upper-arm measurement would have shown 135/85. Or the reverse: a dangerously high pressure might be masked by a poorly positioned cuff.

Evidence From SPRINT and STEP Trials Lands Unevenly

The evidence base for tighter targets is real, but it lands unevenly in a busy clinic. The SPRINT trial, published in 2015, randomized over 9,000 high-risk adults to a systolic target of 120 mmHg versus 140 mmHg. It found a 27% relative reduction in major cardiovascular events and a 25% reduction in all-cause mortality in the intensive group. Those are striking numbers.

But the absolute risk reduction was around 1.6% per year for the composite outcome. That means roughly 60 patients needed to be treated intensively for three years to prevent one major event, a number that varies substantially with baseline risk. For a low-risk 50-year-old, the benefit shrinks; for a diabetic with chronic kidney disease, it grows.

The STEP trial, conducted in China and published in 2021, randomized over 8,500 adults aged 60 to 80 to a systolic target of 130 versus 150. It showed a 26% relative reduction in cardiovascular events, again with modest absolute numbers. The trial also reported more dizziness and hypotension in the intensive group, a reminder that tighter control is not free.

These trials were conducted with meticulous measurement protocols, automated office blood pressure, and frequent follow-up. Replicating that in a Kampala clinic with a wrist cuff and a three-month supply of drugs is not straightforward. The evidence is compelling, but the machinery to implement it is missing.

Why Kampala Lags: Workload, Drug Stock, and Fear

The workload in Kampala's public and private clinics is relentless. A clinician may see 80 patients in a day, many with multiple comorbidities. Hypertension is often a side note in a consultation dominated by malaria, respiratory infections, or diabetes. There is no time to discuss the nuances of target blood pressure when a queue stretches out the door.

Drug stockouts are a recurring problem. The public system relies on a supply chain that frequently runs short of common antihypertensives like amlodipine and enalapril. When a patient returns and the drug they were prescribed is unavailable, the clinician switches to whatever is on the shelf, often at a different dose. This churn makes it impossible to titrate to a precise target.

Fear of hypotension is another brake. Clinicians have seen elderly patients collapse after a dose increase, or kidney function deteriorate when blood pressure drops too fast. The guidelines warn about these risks but offer little practical guidance on how to mitigate them in a low-resource setting. In the face of uncertainty, the default is to be conservative.

Guideline updates rarely reach frontline staff. A new policy document may be published in the capital, but it takes months to filter through training programs, and many clinicians learn about it from a colleague or a social media post. The old 140/90 target stays in their muscle memory because nothing has replaced it.

The Measurement Problem Compounds the Treatment Gap

The measurement problem is not just about wrist cuffs. Even with an upper-arm device, a single office reading often overestimates true blood pressure. The white-coat effect, where anxiety drives pressure up in a clinical setting, is well documented. In Kampala, where the clinic may be hot, crowded, and stressful, that effect is likely amplified.

Home monitoring is rarely used in public facilities. Patients cannot afford devices, and clinicians do not have the time to teach proper technique. The result is that treatment decisions are made on a snapshot that may not reflect reality. A patient with white-coat hypertension might be overtreated, while a patient with masked hypertension, normal in the clinic but high at home, goes undetected.

Automated office blood pressure protocols, where the patient sits alone in a quiet room and a device takes multiple readings, are the gold standard in trials. They are almost nonexistent in Kampala. Even in private clinics with wrist cuffs, the measurement is taken in the consultation room, with the patient talking, the clinician rushing, and the cuff perhaps at the wrong height.

The irony is that all the effort to tighten targets is undermined by a measurement system that can misclassify patients by 10 or 20 mmHg. A guideline that aims for 130/80 is meaningless if the device reads 140/90 when the true pressure is 135/85.

Beyond the Clinic: Patient Perspectives and Community Realities

The gap between guidelines and practice is not only a clinic-side problem. Patients in Kampala face their own barriers to achieving controlled blood pressure, and these interact with the measurement and treatment gaps in ways that amplify the risk.

Cost is a major factor. Many patients pay out-of-pocket for medications and clinic visits. A monthly supply of amlodipine might cost anywhere from a few thousand to tens of thousands of Ugandan shillings, depending on the pharmacy and whether a generic is available. When money is tight, patients may skip doses or stretch prescriptions, leading to fluctuating control that no guideline can address.

Health literacy also plays a role. Hypertension is often called the silent killer because it has no symptoms until it causes a heart attack or stroke. Many patients, feeling well, stop taking their medication once their blood pressure appears to normalize. They do not understand that the medication is the reason they feel well, and that stopping it will allow the pressure to climb again. Clinicians, pressed for time, rarely have the chance to explain this in a way that sticks.

Traditional medicine is another layer. Some patients consult herbalists or use homemade remedies before or alongside formal treatment. While some traditional practices may have mild effects, they are not standardized and can interact unpredictably with antihypertensive drugs. A patient who trusts a herbal tonic more than a clinic prescription may not adhere to the regimen, and the wrist cuff reading at the next visit will reflect that.

Social support is uneven. A patient with a family member who reminds them to take pills and accompanies them to appointments is more likely to stay on track. But many patients, especially the elderly living alone, have no such support. The clinic sees them only when a crisis occurs, and the opportunity for gradual titration is lost.

Community health workers, a mainstay of care for HIV and tuberculosis in Uganda, could be a bridge. They are trained to take blood pressure and provide education, and they are already trusted in many neighborhoods. Extending their role to hypertension follow-up, including home visits and medication reminders, could help close the adherence gap. But funding and training are limited, and their efforts are not yet integrated into the hypertension care pathway.

Practical Fixes: Calibrate, Simplify, and Measure Twice

Fixing the gap does not require expensive technology. The first step is to mandate device validation lists in clinics. Simple lists of validated upper-arm cuffs are available from organizations like the British and Irish Hypertension Society, and they cost nothing to print. Clinics should check that their devices are on the list.

Upper-arm cuffs with the correct cuff size are the next priority. Many clinics use a single adult cuff for everyone, which overestimates pressure in small arms and underestimates it in large ones. A set of small, medium, and large cuffs is cheap and can dramatically improve accuracy.

Adopting automated office blood pressure protocols would help. This means seating the patient alone in a quiet room for five minutes, then taking three readings one minute apart with an automated device. It takes time, but it can be delegated to a nurse or a trained assistant, freeing the clinician to focus on treatment decisions.

Training staff on standardized measurement technique is essential. Positioning the cuff at heart level, supporting the arm, and avoiding caffeine and smoking before the reading are simple steps that reduce variability. Digital decision support, even a simple paper chart or a mobile app, can guide clinicians on when to intensify or de-escalate treatment based on risk.

For patients, simplifying regimens can improve adherence. Once-daily medications are preferred, and fixed-dose combinations, where available, reduce the pill burden. The cost of these combinations may be higher, but the improved adherence could offset that in the long run. Clinicians should also involve patients in setting goals, explaining why the target matters and what to do if they feel dizzy or unwell.

From Airy Numbers to Real Outcomes in Kampala

Tightening targets only makes sense after fixing measurement. A guideline that says 130/80 is aspirational when the tools to measure it are unreliable. The priority should be to ensure that every clinic has a validated device, proper cuff sizes, and a protocol that produces trustworthy numbers.

High-risk patients should be prioritized for intensive control. Those with diabetes, chronic kidney disease, or a history of stroke stand to benefit most from lower targets. For low-risk patients, the trade-off between benefit and harm may not justify pushing below 130, and clinicians should be empowered to make that judgment.

Monitoring for adverse events like falls or kidney injury is critical when intensifying treatment. A simple checklist for symptoms such as dizziness or fatigue, and a basic creatinine test where available, can catch problems early. Clinic-level blood pressure control rates should be tracked, not as a punitive measure, but to see where the gaps are.

The gap between evidence and practice in Kampala is not unique, but it is urgent. Bridging it requires simple, evidence-based tools: better devices, better training, and a willingness to question the numbers that come out of a wrist cuff. Until then, the guidelines will remain a paper exercise, and patients will continue to be treated based on air.

This article is for informational purposes only and is not a substitute for professional medical advice. Always consult a qualified healthcare provider for diagnosis and treatment.